Heidi Lehtola1,2, Juha Hartikainen3, Päivi Hartikainen4, Tuomas Kiviniemi5, Ilpo Nuotio6, Antti Palomäki5, Antti Ylitalo5,7, K E Juhani Airaksinen5, Pirjo Mustonen1. 1. Department of Medicine, Keski-Suomi Central Hospital, Jyvaskyla, Finland. 2. Department of Cardiology, Oulu University Hospital, Oulu, Finland. 3. Heart Center, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland. 4. Neuro Center, Kuopio University Hospital, Kuopio, Finland. 5. Heart Center, Turku University Hospital and University of Turku, Turku, Finland. 6. Department of Acute Internal Medicine, Turku University Hospital and University of Turku, Turku, Finland. 7. Satakunta Central Hospital, Pori, Finland.
Abstract
BACKGROUND: Atrial fibrillation (AF) increases risk of ischemic stroke, and oral anticoagulation (OAC) increases risk of intracerebral hemorrhage (ICH). This study aimed to compare OAC-treated AF patients with an ischemic stroke/transient ischemic attack (TIA) or spontaneous ICH as their first lifetime cerebrovascular event, especially focusing on patients with therapeutic international normalized ratio (INR). HYPOTHESIS: We assumed that in AF patients suffering ischemic stroke/TIA or ICH, patient characteristics could be different in patients with therapeutic INR than in patients with warfarin. METHODS: FibStroke is a multicenter, retrospective registry collating details of AF patients with ischemic stroke/TIA or intracranial hemorrhage in 2003-2012. This substudy included AF patients on OAC with first lifetime ischemic stroke/TIA or spontaneous ICH. RESULTS: A total of 1457 patients with 1290 ischemic strokes/TIAs and 167 ICHs were identified. Of these, 553 (42.9%) strokes/TIAs and 96 (57.5%) ICHs occurred in patients with INR within therapeutic range. During OAC with therapeutic INR, congestive heart failure (odds ratio [OR]: 2.33, 95% confidence interval [CI]: 1.18-4.58) and hypercholesterolemia (OR: 2.52, 95% CI: 1.51-4.19) were more common in patients with ischemic stroke/TIA, whereas a history of bleeding (OR: 0.30, 95% CI: 0.11-0.82) was less common when compared with patients with ICH. In the whole cohort, renal impairment (OR: 1.86, 95% CI: 1.23-2.80) and mechanical valve prosthesis (OR: 4.41, 95% CI: 1.32-14.7) were overrepresented in patients with stroke/TIA, whereas aspirin use (OR: 0.52, 95% CI: 0.30-0.91) and high INR (OR: 0.40, 95% CI: 0.33-0.48) were overrepresented in patients with ICH. CONCLUSIONS: In anticoagulated AF patients with therapeutic INR and first lifetime cerebrovascular event, congestive heart failure and hypercholesterolemia were associated with ischemic stroke/TIA and history of bleeding with ICH.
BACKGROUND:Atrial fibrillation (AF) increases risk of ischemic stroke, and oral anticoagulation (OAC) increases risk of intracerebral hemorrhage (ICH). This study aimed to compare OAC-treated AFpatients with an ischemic stroke/transient ischemic attack (TIA) or spontaneous ICH as their first lifetime cerebrovascular event, especially focusing on patients with therapeutic international normalized ratio (INR). HYPOTHESIS: We assumed that in AFpatients suffering ischemic stroke/TIA or ICH, patient characteristics could be different in patients with therapeutic INR than in patients with warfarin. METHODS: FibStroke is a multicenter, retrospective registry collating details of AFpatients with ischemic stroke/TIA or intracranial hemorrhage in 2003-2012. This substudy included AFpatients on OAC with first lifetime ischemic stroke/TIA or spontaneous ICH. RESULTS: A total of 1457 patients with 1290 ischemic strokes/TIAs and 167 ICHs were identified. Of these, 553 (42.9%) strokes/TIAs and 96 (57.5%) ICHs occurred in patients with INR within therapeutic range. During OAC with therapeutic INR, congestive heart failure (odds ratio [OR]: 2.33, 95% confidence interval [CI]: 1.18-4.58) and hypercholesterolemia (OR: 2.52, 95% CI: 1.51-4.19) were more common in patients with ischemic stroke/TIA, whereas a history of bleeding (OR: 0.30, 95% CI: 0.11-0.82) was less common when compared with patients with ICH. In the whole cohort, renal impairment (OR: 1.86, 95% CI: 1.23-2.80) and mechanical valve prosthesis (OR: 4.41, 95% CI: 1.32-14.7) were overrepresented in patients with stroke/TIA, whereas aspirin use (OR: 0.52, 95% CI: 0.30-0.91) and high INR (OR: 0.40, 95% CI: 0.33-0.48) were overrepresented in patients with ICH. CONCLUSIONS: In anticoagulated AFpatients with therapeutic INR and first lifetime cerebrovascular event, congestive heart failure and hypercholesterolemia were associated with ischemic stroke/TIA and history of bleeding with ICH.
Authors: Alec Vahanian; Ottavio Alfieri; Felicita Andreotti; Manuel J Antunes; Gonzalo Barón-Esquivias; Helmut Baumgartner; Michael Andrew Borger; Thierry P Carrel; Michele De Bonis; Arturo Evangelista; Volkmar Falk; Bernard Iung; Patrizio Lancellotti; Luc Pierard; Susanna Price; Hans-Joachim Schäfers; Gerhard Schuler; Janina Stepinska; Karl Swedberg; Johanna Takkenberg; Ulrich Otto Von Oppell; Stephan Windecker; Jose Luis Zamorano; Marian Zembala Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983
Authors: Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245
Authors: S Curtze; D Strbian; A Meretoja; J Putaala; H Eriksson; E Haapaniemi; S Mustanoja; T Sairanen; J Satopää; H Silvennoinen; M Niemelä; M Kaste; T Tatlisumak Journal: Eur J Neurol Date: 2014-01-21 Impact factor: 6.089
Authors: K E Juhani Airaksinen; Toni Grönberg; Ilpo Nuotio; Marko Nikkinen; Antti Ylitalo; Fausto Biancari; Juha E K Hartikainen Journal: J Am Coll Cardiol Date: 2013-07-10 Impact factor: 24.094
Authors: Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin Journal: N Engl J Med Date: 2011-08-27 Impact factor: 91.245
Authors: Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer Journal: N Engl J Med Date: 2003-09-11 Impact factor: 91.245
Authors: Alessandro Mauriello; Giuseppe M Sangiorgi; Renu Virmani; Santi Trimarchi; David R Holmes; Frank D Kolodgie; David G Piepgras; Giulia Piperno; Doriana Liotti; Jagat Narula; Paolo Righini; Arnaldo Ippoliti; Luigi G Spagnoli Journal: Atherosclerosis Date: 2009-08-03 Impact factor: 5.162
Authors: A Palomäki; P Mustonen; J E K Hartikainen; I Nuotio; T Kiviniemi; A Ylitalo; P Hartikainen; K E J Airaksinen Journal: Eur J Neurol Date: 2015-08-11 Impact factor: 6.089
Authors: Heidi Lehtola; Juha Hartikainen; Päivi Hartikainen; Tuomas Kiviniemi; Ilpo Nuotio; Antti Palomäki; Antti Ylitalo; K E Juhani Airaksinen; Pirjo Mustonen Journal: Clin Cardiol Date: 2018-05-10 Impact factor: 2.882
Authors: Fabian Schaub; Alexandros A Polymeris; Sabine Schaedelin; Lisa Hert; Louisa Meya; Sebastian Thilemann; Christopher Traenka; Benjamin Wagner; David Seiffge; Henrik Gensicke; Gian Marco De Marchis; Leo Bonati; Stefan T Engelter; Nils Peters; Philippe Lyrer Journal: J Am Heart Assoc Date: 2021-12-22 Impact factor: 6.106